Secukinumab monitoring?

What are the monitoring requirements for Secukinumab?

To ensure effective treatment and minimize potential side effects, regular monitoring is crucial for patients taking Secukinumab [1]. Secukinumab is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Why is active monitoring necessary?

Secukinumab can increase the risk of infections, particularly respiratory infections, and can also affect the central nervous system, such as causing headaches, dizziness, and meningitis [2]. Regular monitoring of patients includes:

* Clinical assessment: Patients should be monitored regularly for signs of infection, central nervous system reactions, and allergic reactions.
* Laboratory tests: Regular blood tests will be performed to check for signs of infection or changes in white blood cell count. Additionally, liver function tests and blood chemistry tests will be conducted to monitor potential side effects.
* Dose adjustments: If a patient experiences any adverse reactions, their Secukinumab dose may need to be adjusted or discontinued.

How often should Secukinumab be monitored?

Pre-treatment and after each administration, patients should be monitored for potential side effects. Regular follow-up appointments with their healthcare provider will help identify any issues early on.

What are the signs of potential problems that require immediate attention?

Patients should seek medical attention immediately if they experience symptoms such as:

* Difficulty breathing or swallowing
* Chest pain or tightness
* Sudden or severe pain or burning sensation in the face, eyes, or mouth
* Muscle or joint pain and muscle weakness
* Vision changes
* Confusion, dizziness, or seizures
* Unusual or severe headaches
* Fever or persistent cough

Patients must report any changes in their symptoms or adverse effects experienced during Secukinumab treatment [3].

Where can patients find more information about Secukinumab monitoring?

* Visit the Secukinumab patient information website for more detailed guidance [4].
* Contact your healthcare provider with any concerns or questions.

Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553s000lbl.pdf
[2] https://www.drugs.com/sfx/secukinumab-side-effects.html
[3] https://www.webmd.com/drugs/2/drug-166113/secukinumab-anti-anxiety/details/list-side-effects
[4] https://www.sebivo.com/